Tag Archives: GBM

October, 2018

December, 2017

September, 2017

  • 15 September

    FDA Approves Amgen and Allergan’s Mvasi for the Treatment of Five Types of Cancer

    THOUSAND OAKS, Calif., Sept. 14, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin® (bevacizumab). MVASI is the first anti-cancer biosimilar, as well as the first bevacizumab biosimilar, approved by the FDA. MVASI is …

May, 2017

April, 2017

March, 2017

February, 2017

  • 7 February

    GW Pharma’s Cannabis-Derived Drug Shows Promise in Brain Cancer Study

    London, UK, 7 Feb 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination …

October, 2016

  • 31 October

    Roche Licenses its PI3K Pathway Brain Cancer Drug to Novogen

    SYDNEY, Oct. 30, 2016 /PRNewswire/ — Australian oncology-focused biotechnology company, Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has entered into a worldwide licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase (PI3K) pathway. The …

July, 2016

June, 2016